Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Completed
Elan Pharmaceuticals
Phase 3
2001-11-01
The purpose of this study is to determine the safety and efficacy of natalizumab in the
treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis
(MS). It is hoped that natalizumab will prevent certain types of white blood cells from
moving out of the bloodstream into organs, including the brain, that are being damaged by
autoimmune disease (a disease in which the body's own immune system attacks certain organs).
These white blood cells are thought to cause inflammation that can result in lesions (small
areas of damage) in the brain. These lesions are thought to be the cause of relapses and
disability in MS.
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
Completed
Biogen
Phase 3
2001-11-01
The purpose of this study is to determine the safety and efficacy of natalizumab in the
treatment of individuals who have been diagnosed with relapsing remitting multiple sclerosis
(MS). It is hoped that natalizumab will prevent certain types of white blood cells from
moving out of the bloodstream into organs, including the brain, that are being damaged by
autoimmune disease (a disease in which the body's own immune system attacks certain organs).
These white blood cells are thought to cause inflammation that can result in lesions (small
areas of damage) in the brain. These lesions are thought to be the cause of relapses and
disability in MS.
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
Completed
Elan Pharmaceuticals
Phase 3
2002-01-01
The purpose of this study is to determine if natalizumab in combination with AVONEX is safe
and effective in delaying progression of individuals diagnosed with relapsing remitting
Multiple Sclerosis (MS).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
